Hummingbird Bioscience is a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need
Singapore
Joined July 2015
- Tweets270
- Following152
- Followers215
- Likes8
Earlier this month, Hummingbird Bioscience was delighted to support Pathlight School (Ang Mo Kio) for Discovery Day, a day dedicated to bringing Science, Math and English concepts to life and inspiring curiosity among students. #CSR #STEM #education
We also had the opportunity to share a comic illustrating the drug discovery and development process, helping students better understand the science behind the work we do at Hummingbird Bioscience.
Jerome Boyd-Kirkup, Chief Scientific Officer, and James Garner, President will be attending BioCentury China Healthcare Summit in Shanghai (2-4 November 2026).
We look forward to connecting with the biopharma community. #biocentury #biopharma
Ben Ayers, VP, ADCs will be at Antibody Engineering & Therapeutics Asia (19-21 Oct, Kyoto) to share about the potential of dual-payload ADCs to shift the treatment paradigm for immune & inflammatory diseases. Jerome Boyd-Kirkup, Chief Scientific Officer, will also be at the event
If you will be there, catch up with them to learn more about our latest developments.
#ADCs #antibodydrugconjugates #AntibodyEng #AETAsia #AET
Last Wednesday, Hummingbird Bioscience was honored on the NextGen Tech 30 list as one of Asia’s top technology companies. Thank you @graniteasia and judges for the recognition, and @NVIDIA for the referral.
Hummingbird Bioscience is leveraging NVIDIA Nemotron open models to accelerate AI analysis of biological data. With NVIDIA’s accelerated computing, we are working to better understand drug toxicity and inform our drug development. We thank @NVIDIA for the referral to participate.
Granite Asia press release: bit.ly/4hvtWSK
Read more about the recognition:
The Business Times: bit.ly/4j34sNH
CNA: bit.ly/4hJmceD
NextGen Tech 30: bit.ly/4yhz0PS
#NextGenTech30 #Innovation #AI
Press release: bit.ly/47tRktK
Hummingbird Bioscience announces first patient dosed in Phase II trial of HMBD-001 and cetuximab in advanced squamous cell cancers
Press release: bit.ly/47tRktK
The advancement of HMBD-001 provides important clinical-stage validation of Hummingbird Bioscience’s AIMM platform, demonstrating the application of AI across the drug-development continuum.
We’re using #AI to understand toxicity, a difficult problem in #drugdevelopment. With @LynxKite, using @NVIDIA Nemotron open models, we’re building a Toxicity Knowledge Graph to connect complex evidence and prioritize questions for development. bit.ly/3SZd6lT
This #NVIDIAAIDay, read NVIDIA’s blog to learn more about how technology leaders in Southeast Asia are building with Nemotron open models: bit.ly/4hiLsIu
#ArtificialIntelligence #Toxicology #ADCs #NVIDIA #NVIDIAInception
Yesterday, members of the Hummingbird Bioscience team took part in the Race Against Cancer 2026.
Having participated in the race for several years, we are proud to continue supporting this meaningful initiative.
Support Singapore Cancer Society’s efforts to advance cancer care at raceagainstcancer.org.sg/
#RaceAgainstCancer #RAC #RAC2026
Press release: bit.ly/3T8nqaW
Hummingbird Bioscience appoints Dr. James Garner as President.
Akshaya Bansal, Executive Director, ADC Platforms, will be at ADC & Bioconjugate East Asia to present Hummingbird Bioscience’s dual-payload #ADC platform.
If you will be at the event, connect with Akshaya to learn more about our latest developments.
#ADCBio2026
Hummingbird Bioscience is addressing complex challenges in drug discovery and development.
At @GoogleCloud_SG #StartupSummit Singapore, our CTO Konrad Paszkiewicz shared how we’re using agentic #AI to scale scientific reasoning and accelerate drug discovery and development.